In a filing, PTC Therapeutics Inc revealed its EXEC. VP AND CLO Boulding Mark Elliott unloaded Company’s shares for reported $0.21 million on Oct 07 ’25. In the deal valued at $63.43 per share,3,375 shares were sold. As a result of this transaction, Boulding Mark Elliott now holds 103,901 shares worth roughly $6.87 million.
Then, Reeve Emma sold 25,562 shares, generating $1,686,024 in total proceeds. Upon selling the shares at $65.96, the Director now owns 10,332 shares.
Before that, Jacobson Allan Steven sold 12,000 shares. PTC Therapeutics Inc shares valued at $780,000 were divested by the Director at a price of $65.00 per share. As a result of the transaction, Jacobson Allan Steven now holds 17,451 shares, worth roughly $1.15 million.
Truist initiated its PTC Therapeutics Inc [PTCT] rating to a Buy in a research note published on June 17, 2025; the price target was $80. A number of analysts have revised their coverage, including BofA Securities’s analysts, who increased its forecast for the stock in early May from “a Neutral” to “a Buy”. Citigroup also remained covering PTCT and has increased its forecast on May 07, 2025 with a “Neutral” recommendation from previously “Sell” rating. BofA Securities revised its rating on March 11, 2025. It rated PTCT as “a Neutral” which previously was an “an Underperform”.
Price Performance Review of PTCT
On Tuesday, PTC Therapeutics Inc [NASDAQ:PTCT] saw its stock jump 0.05% to $66.09. Over the last five days, the stock has gained 3.42%. PTC Therapeutics Inc shares have risen nearly 71.71% since the year began. Nevertheless, the stocks have risen 46.41% over the past one year.
How much short interest is there in PTC Therapeutics Inc?
A steep rise in short interest was recorded in PTC Therapeutics Inc stocks on 2025-09-30, growing by 0.49 million shares to a total of 7.14 million shares. Yahoo Finance data shows the prior-month short interest on 2025-08-29 was 6.64 million shares. There was a rise of 6.92%, which implies that there is a positive sentiment for the stock.
The most recent change occurred on March 07, 2025 when Scotiabank began covering the stock and recommended ‘”a Sector perform”‘ rating along with a $55 price target.
